3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Phase 2/3
1
Status
Withdrawn
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Head & Neck
1
Endocrine
1
Conditions
Carcinoma, Non-Small-Cell Lung
190
Lung Neoplasms
67
Ovarian Neoplasms
64
Breast Neoplasms
38
Fallopian Tube Neoplasms
33
Small Cell Lung Carcinoma
31
Parkinson Disease 4, Autosomal Dominant Lewy Body
27
Carcinoma, Ovarian Epithelial
24
Uterine Cervical Neoplasms
22
Triple Negative Breast Neoplasms
22
Squamous Cell Carcinoma of Head and Neck
19
Neuroblastoma
17
Carcinoma
17
Adenocarcinoma of Lung
17
Neoplasm Metastasis
15
Endometrial Neoplasms
14
Neoplasms
12
Head and Neck Neoplasms
11
Recurrence
8
Peritoneal Neoplasms
8
Carcinoma, Transitional Cell
8
Esophageal Neoplasms
7
Central Nervous System Neoplasms
7
Brenner Tumor
7
Urinary Bladder Neoplasms
6
Lung Diseases
6
Adenocarcinoma, Bronchiolo-Alveolar
6
Thoracic Neoplasms
5
Testicular Neoplasms
5
Respiratory Tract Neoplasms
5
Interventions
Iodine-131
3
Thyrotropin Alfa
2
vandetanib
1
lenvatinib
1
fosbretabulin
1
combretastatin
1
cabozantinib
1
Thyroidectomy
1
Sorafenib
1
Ropivacaine
1
Radiotherapy
1
Paclitaxel
1
Neck Dissection
1
Metformin
1
Epinephrine
1
Carboplatin
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 3
×
Thyroid Neoplasms
×
Carboplatin
×
Clear all
NCT01701349
2014-05-01
FACT2
Mateon Therapeutics
Phase 3
Withdrawn